SIMCERE Aktie

 

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Pharma - Der Pharmakonzern Roche hat mit einem chinesischen Unternehmen eine Lizenzvereinbarung für einen Antikörper-Kandidaten abgeschlossen....

Simcere Zaiming schließt exklusive Lizenzvereinbarung mit Roche über die weltweite Entwicklung von SIM0660...

Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

Von Megan Cheah DOW JONES--Der Schweizer Pharmakonzern Roche hat eine Lizenzvereinbarung mit dem chinesischen Unternehmen Simcere Pharmaceutical zur Entwicklung eines Medikaments gegen Blutkrebs geschlossen. Roche zahlt laut Simcere ......

NANJING, China, Sept. 1, 2026 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group (2096.HK) today announced that it has entered into an exclusive global licensing agreement with Roche for the development and commercialization of SIM0660, a tri-specific antibody......

Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development...

SIMCERE PHARMA (02096.HK) announced that the group has signed an exclusive licensing agreement with F. Hoffmann-La Roche Ltd ("Roche"). Under the terms of the agreement, Roche will obtain exclusive global rights to develop, manufacture and commercialize SIM0660, a CD79a/CD19/CD3 trispecific antibody. This licensing deal marks th......

SIMCERE PHARMA (02096.HK) announced that it has resolved to exercise its authorization to repurchase shares on the open market at appropriate times, with a total amount not exceeding RMB1 billion. (de/d)~AASTOCKS Financial NewsWebsite: www.aastocks.comThis article was automatically translated by AI, the Chinese version should be......

SIMCERE PHARMA (02096.HK) announced its interim results for the six months ended June 2026. Revenue was RMB4.58 billion, up 27.8% YoY. Net profit was RMB829 million, increasing 37.9%, mainly due to growth in revenue from innovative drugs and licensing income. EPS was RMB0.32. No dividend was declared. (d)~AASTOCKS Financial News......

SIMCERE PHARMA (02096.HK) issued a positive profit alert, expecting net profit for the six months ended June 2026 to reach approximately RMB810-860 million, compared with the restated net profit of approximately RMB601 million in the corresponding period of 2025, representing a YoY increase of approximately 34.8-43.1%. In additi......

Under the deal, Simcere will provide funding for exploratory research on a first-in-class novel molecule in the respiratory field. If the research is successful, Simcere will have the The post Simcere and Stanford partner to develop IPF therapies appeared first on Pharmaceutical Business review....

SIMCERE PHARMA (02096.HK) announced that SIM0689, a PD-1/VEGF-targeting bispecific antibody independently developed by the group, has received a Clinical Trial Approval Notice from the National Medical Products Administration (NMPA) of China. The drug is planned to commence clinical trials for advanced solid tumors.SIM0689 is a ......

Simcere Pharmaceutical schließt eine Forschungskooperationsvereinbarung mit Stanford Medicine zur Entwicklung innovativer Therapien für Patienten mit idiopathischer Lungenfibrose...

Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis...

SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing......

SIMCERE PHARMA (02096.HK) announced that the Group entered into an exclusive promotion service agreement with PrimeGenX Therapeutics in relation to Pumecitinib Gel. Pursuant to the Agreement, the Group will obtain the exclusive promotion rights for Pumecitinib Gel for all dermatology indications in Mainland China, Hong Kong, and......

BELTSVILLE, Md., June 01, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel therapies to treat cancer, and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere Zaiming) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced the presentation of positive Phase 1 dose escalation data for SIM0505 at the American Society for Clinical Oncology (ASCO 2026) in Chicago, IL (poster #246). SIM0505 is an investigational antibody drug conjugate (ADC) targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload. NextCure plans to host a virtual KOL Event on Tuesday, June 2, 2026 (register here) to review these data....

SIMCERE PHARMA (02096.HK) announced that its self-developed LRRC15-targeting antibody-drug conjugate, SIM0613 for injection, has received a Clinical Trial Approval Notice issued by the National Medical Products Administration of China. The drug is planned to commence clinical trials for advanced solid tumors. (ec/w)~AASTOCKS Fin......

BELTSVILLE, Md., May 04, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), today announced initiation of the dose optimization portion of the Phase 1 study of SIM0505, focusing on patients with platinum-resistant ovarian cancer. SIM0505 is an investigational antibody drug conjugate (ADC) comprised of an antibody that targets Cadherin-6 (CDH6) and a proprietary topoisomerase 1 inhibitor (TOPOi) payload....